Protalix BioTherapeutics (PLX) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-26.74M
Share based compensation	765K
Depreciation and impairment of fixed assets
Financial expenses, net (mainly exchange differences)	-375K
Changes in accrued liability for employee rights upon retirement	-31K
Gain on amounts funded in respect of employee rights upon retirement
Gain on sale of fixed assets
Increase (decrease) in deferred revenues	-291K
Decrease in inventories	907K
Decrease (increase) in accounts receivable	-1.36M
Increase (decrease) in accounts payable and accruals	367K
Net cash used in operating activities	-24.76M
Purchase of property and equipment	-732K
Amounts funded in respect of employee rights upon retirement, net	7K
Net cash used in investing activities	-725K
Issuance of shares, net of issuance cost
Exercise of options	0
Net cash provided by financing activities
EFFECT OF EXCHANGE RATE CHANGES ON CASH	431K
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	-25.05M
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	76.37M
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD	51.32M
Purchase of property and equipment	642K
Issuance cost not yet paid and accruals - other

Entities mentioned with PLX

View All Entities